高剂量阿仑单抗联合环孢素对比他克莫司、甲氨蝶呤和西罗莫司预防慢性移植物抗宿主病
83例血液恶性肿瘤患者接受靶向淋巴清除化疗后行减低强度预处理异基因造血干细胞移植,随机分为阿仑单抗联合环孢素组(AC,n=44)或他克莫司、甲氨蝶呤和西罗莫司组(TMS,n=39),主要终点为重度慢性移植物抗宿主病(cGVHD)累积发生率。AC组1年和5年重度cGVHD发生率均低于TMS组(0% vs 10.3%和4.5% vs 28.5%;总体P=.0002),但AC组3-4级感染率和复发率更高(52% vs 21%;P=.003),5年无GVHD无复发生存或总生存无差异。
要点
- AC组重度cGVHD 1年0% vs TMS组10.3%,5年4.5% vs 28.5%(总体P=.0002)。
- AC组复发率52% vs TMS组21%(P=.003),3-4级感染率更高(P=.02)。
- 两组5年无GVHD无复发生存或总生存无差异。
核心结论
- 以阿仑单抗为基础的方案成功降低了减低强度预处理异基因造血干细胞移植后cGVHD的发生率和严重程度,并产生独特的免疫调节特征,可能降低了cGVHD发生率和严重程度,但感染和复发增加导致长期随访后无生存获益。
研究设计与样本
- 随机对照试验,83例血液恶性肿瘤患者接受靶向淋巴清除化疗后行减低强度预处理异基因造血干细胞移植,使用无关供者外周血干细胞,随机分为AC组(阿仑单抗联合环孢素,n=44)或TMS组(他克莫司、甲氨蝶呤和西罗莫司,n=39),主要终点为重度cGVHD累积发生率。
主要发现
- AC组 vs TMS组1年重度cGVHD发生率为0% vs 10.3%,5年为4.5% vs 28.5%(总体P=.0002)。
- AC组 vs TMS组任何级别cGVHD(P=.003)和中重度cGVHD(P<.0001)发生率更低。
- AC组 vs TMS组3-4级感染率更高(P=.02),复发率为52% vs 21%(P=.003)。
- 两组5年无GVHD无复发生存或总生存无差异。
- AC组严重耗竭初始T细胞重建,导致6个月时T细胞受体库多样性降低、CD4Treg和CD8Tscm群体减少,但Treg与初始T细胞比值更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion for cGVHD prophylaxis has been explored in the myeloablative setting, its effects after reduced-intensity conditioning (RIC) are not well described. Patients (N = 83) with hematologic malignancies underwent targeted lymphodepletion chemotherapy followed by a RIC allo-HSCT using peripheral blood stem cells from unrelated donors. Patients were randomized to 2 GVHD prophylaxis arms: alemtuzumab and cyclosporine (AC; n = 44) or tacrolimus, methotrexate, and sirolimus (TMS; n = 39), with the primary end point of cumulative incidence of severe cGVHD. The incidence of severe cGVHD was lower with AC vs TMS prophylaxis at 1- and 5-years (0% vs 10.3% and 4.5% vs 28.5%; overall, P = .0002), as well as any grade (P = .003) and moderate-severe (P < .0001) cGVHD. AC was associated with higher rates of grade 3 to 4 infections (P = .02) and relapse (52% vs 21%; P = .003) with no difference in 5-year GVHD-free-, relapse-free-, or overall survival. AC severely depleted naïve T-cell reconstitution, resulting in reduced T-cell receptor repertoire diversity, smaller populations of CD4Treg and CD8Tscm, but a higher ratio of Treg to naïve T-cells at 6 months. In summary, an alemtuzumab-based regimen successfully reduced the rate and severity of cGVHD after RIC allo-HSCT and resulted in a distinct immunomodulatory profile, which may have reduced cGVHD incidence and severity. However, increased infections and relapse resulted in a lack of survival benefit after long-term follow-up. This trial was registered at www.ClinicalTrials.gov as #NCT00520130.
引用
- Holtzman NG, Curtis LM, Salit RB, et al. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Adv. 2024. PMID: 38669315. doi:10.1182/bloodadvances.2023010973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。